Altium 365 Integrates with SiliconExpert, Delivering Unmatched Component Data Access to Designers Worldwide
1.8.2023 16:00:00 EEST | Business Wire | Press release
Altium, LLC (ASX: ALU), a global leader in electronics design systems, announced its integration collaboration with SiliconExpert, a leading provider of electronic component data and parts management software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801837887/en/
Altium 365 meets SiliconExpert (Graphic: Business Wire)
This integration empowers engineers, procurement professionals, and other stakeholders using Altium 365, an electronics development platform, with direct access to comprehensive, real-time component data whenever it is needed during the design and product lifecycle.
With SiliconExpert's data on over a billion electronic parts, Altium 365 users can soon access even more detailed component information than they have had before, from the simplest resistors to the most complex ICs. The data, sourced directly from manufacturers, helps ensure unparalleled accuracy and reliability in decision-making.
"We are thrilled to build the integration as part of a continuing collaboration between SiliconExpert and Altium 365," says Ananth Avva, GM and Sr. Vice President of Cloud Platform at Altium. "Supply chain of components in the electronics lifecycle management remains a key topic for many of our customers. We are continuing to enrich component data for our customers, and Silicon Expert is one source that is in high demand. We believe this integration will continue to improve the way teams across all disciplines - from designers to operations, procurement, finance, and quality and compliance - approach component selection, risk analysis, and compliance management."
The integration will offer:
- Comprehensive Component Data: Extensive component details, from lifecycle status to environmental compliance, right within the ActiveBOM.
- Informed Decision-making: Real-time component data to aid in making informed decisions about component selection, enhancing design quality, efficiency, and compliance.
- Risk Management: Detailed metrics, including Year-to-End-of-Life (YTEOL) date, multi-sourcing, and inventory risks, allow for proactive risk management and strategic decision-making.
- Accuracy and Reliability: High-quality, up-to-date data backed by SiliconExpert's strict data integrity protocols.
Altium continues to innovate in the PCB design software market, aiming to unify all aspects of the electronics product design to realization process into a single, cohesive environment. This integration with SiliconExpert reaffirms Altium's commitment to providing a comprehensive, user-friendly solution that caters not only to electronics designers but also to operations, procurement, and supply chain professionals. This approach helps ensure streamlined coordination and enhanced decision-making across all stages of product development and lifecycle for Altium’s customers.
The SiliconExpert integration will be available to Altium 365 users later this month. For more information, visit https://www.altium.com/altium-365/supply-chain/siliconexpert.
About Altium
Altium, LLC (ASX: ALU) is a global software company headquartered in San Diego, California, who is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801837887/en/
Contact information
Fabian Winkler
Product Marketing Manager, Altium LLC
fabian.winkler@altium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom